XPO1 and acute myeloid leukemia: Targeting of this complex, and thereby the molecular export from the nucleus to the cytoplasm, is now regarded as a possible therapeutic strategy in human AML, and pharmacological inhibition of Exportin 1/XPO1 has been investigated in several clinical studies [4].